| Inclusion Criteria |
| Male patient diagnosed with prostate adenocarcinoma, confirmed by histopathology |
| Age ≥50 years old |
| Low- and Intermediate-risk prostate carcinoma as defined by the NCCN version 2.2012 |
| • Low-risk: ≤ csT2a, Gleason ≤ 6, PSA ≤ 10 |
| • Intermediate-risk: = csT2b-c, Gleason 7, PSA=10-20 |
| Surgical clearance |
| ECOG performance status of 0-1 |
| No pubic arch interference or anatomical variants that would preclude a satisfactory implant as determined by pre-operative radiologic assessment (CT, MRI, ultrasound as indicated) |
| Pre-operative approval by primary care provider, cardiologist or other qualified clinician |
| Exclusion Criteria |
| History of prior radiotherapy to prostate or pelvis |
| Prior prostate surgery such as transurethral resection of the prostate (TURP) |
| History of prior chemotherapy for prostate cancer |
| Significant pelvic CT/MRI artifact distortion due to prior surgical implants (e.g. hip implants) |
| High-risk prostate carcinoma: >csT3, Gleason 8-10, PSA >20 |
| Prostate volume >60 cm3 |
| History of autoimmune disorders (e.g. inflammatory bowel disease, CREST syndrome, scleroderma, lupus) |
| Clinical, radiological or pathological confirmed/suspected T3b, N1, or M1 per 7th ed. AJCCC staging manual |
| Pre-existing rectal fistula |
| Medically contraindicated for surgery or anesthesia |
| Determined to be unfit for procedure by primary care provider, cardiologist, or other qualified clinician |
| Abbreviations: PSA=prostate specific antigen, NCCN=National Cancer Cooperative Network, ECOG=Eastern Cooperative Oncology Group |
